672 Dupont Street, Suite 204
M6G 1Z6 Toronto, Ontario
Canada
Phone: +1 416 7037709
Fax: +1-866-422-0962
http://www.interfaceware.com
Manufacturers
Company Contacts
Department/ Name Address
Alan Mclaren alan.mclaren@interfaceware.com
Andreas Theodosiou andreas.theodosiou@interfaceware.com
Company Figures
Year of foundation 1997
Area of business Communication and Information Technology
Company Profile
iNTERFACEWARE, Inc.
HL7 INTEGRATION: iNTERFACEWARE is committed to simplifying the exchange of electronic healthcare data not only through the provision of industry leading technology, support and service, but also by providing well documented processes and guidelines that fully address the data integration problem. Uniting strong technical ability with intense customer focus, iNTERFACEWARE makes integration easy.
Founded in 1997, iNTERFACEWARE is an HL7 solutions provider with industry-leading technology, trusted business expertise, highly-skilled personnel and a proven track record.
Our products and services make exchanging electronic healthcare data easy for healthcare providers and software vendors alike.
We have extensive experience with some of the world’s leading organizations, including IBM and Oracle, who depend on iNTERFACEWARE’s software solutions to integrate HL7 with their systems. Our partnership with leading organizations and impressive customer base is a testament to our understanding of the healthcare market’s data integration needs and common HL7 business issues, which enable us to deliver complete business solutions to our clients.
iNTERFACEWARE has extensive quality assurance policies and procedures that ensure all our products are engineered to the highest degree.
We understand that customers rely on us for superior products. Both vendors and health care providers can rest assured that our software undergoes rigorous testing and review to ensure it passes the highest standards. iNTERFACEWARE is proud to note that our QA processes have been audited and approved by several satisfied customers who are themselves subject to FDA review.